Could a vaccine made from your own cells tame progressive MS?
NCT ID NCT07020715
First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This phase IIa trial tests a new cell therapy for people with progressive multiple sclerosis (MS). Doctors take a patient's own blood cells, turn them into 'tolerogenic dendritic cells' in a lab, and inject them back to calm the immune system and stop it from attacking the nerves. The study will enroll 14 participants and measure whether the treatment can slow disability and is safe to use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Germans Trias i Pujol Hospital (HUGTiP)
Badalona, 08916, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
-
Universitair Ziekenhuis Antwerpen (UZA)
Edegem, 2650, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tolerogenic dendritic cells (tolDC) made from the patient's own blood cells
What this could lead to
If it works, this could point toward a way to slow or stop disability progression in progressive multiple sclerosis without strong immune-suppressing drugs.
What could go wrong
This is a very early, small trial (14 people) testing safety and basic effectiveness. The treatment is complex and personalized, so results may not apply broadly, and it may not slow the disease at all.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.